Professor Hillmen, who is lead investigator for the CLL208 trial, explained: "Rituximab's capabilities in combination with FC chemotherapy have been well proven, however this trial examined its interaction with chlorambucil, which is the standard treatment prescribed for frailer patients with CLL.    From Wordnik.com.  [Health News from Medical News Today] Reference

In a separate UK-only study, CLL208, also presented at ASH, rituximab was trialled in combination with chlorambucil chemotherapy in previously untreated CLL patients.    From Wordnik.com.  [Health News from Medical News Today] Reference

Alemtuzumab is superior to chlorambucil as first-line treatment for patients with chronic lymphocytic leukemia (CLL), according to results of a study published in the December issue of the Journal of Clinical Oncology.    From Wordnik.com.  [xml's Blinklist.com] Reference

Genzyme Corp. and Berlex Inc. have announced results from CAM307, an international Phase III clinical trial comparing Campath (alemtuzumab) with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia.    From Wordnik.com.  [xml's Blinklist.com] Reference

The interim results from this study indicate that adding rituximab to this commonly used chemotherapy improves the overall response rate by 17.3 per cent compared to historical data from patients in another UK study (CLL4) who received chlorambucil alone.    From Wordnik.com.  [Health News from Medical News Today] Reference